In Brief 
INTRODUCTION
Innate lymphoid cells (ILCs) are ''lineage antigen'' (Lin) negative cells that are enriched in lymphoid tissues and play multiple roles in health and disease (Artis and Spits, 2015) . ILCs include cytotoxic natural killer (NK) cells and three types of non-cytotoxic ''helper'' ILCs designated as ILC1s, ILC2s, and ILC3s. All ILCs lack rearranged antigen-specific receptors, yet they share many features with adaptive T cell subsets. NK cells express the transcription factors (TFs) T-BET and EOMES, produce interferon-g (IFN-g), and kill tumor and virally-infected cells (Sun and Lanier, 2011) . ILC1s are T-BET + EOMES À and produce IFN-g, and while rare in the healthy gut, ILC1s are expanded in Crohn's disease (Bernink et al., 2013; Fuchs et al., 2013; Klose et al., 2014) . ILC2s express the TFs GATA3 and RORa and produce type 2 cytokines in response to helminth infections (Mjö sberg et al., 2011; Moro et al., 2010; Neill et al., 2010) . ILC3s express the TFs AHR and RORgt and secrete IL-17 and/or IL-22 to regulate mucosal inflammation (Cella et al., 2009; Cupedo et al., 2009; Hughes et al., 2009 ). Human ILCs can be identified by flow cytometry among Lin À lymphocytes using subset associated markers. NK cells express CD16, CD56, CD94, NKG2A, NKG2C, NKp80, and/or killer immunoglobulin-like receptors (KIRs) (Scoville et al., 2017) ; ILC2s express CD294 and/or KLRG1 (Huang et al., 2015; Mjö sberg et al., 2011) ; ILC3s express CD117 and NKp44 (Cella et al., 2009; Cupedo et al., 2009; Hughes et al., 2009) ; and ILC1s can be identified as Lin À lymphocytes that lack NK cell, ILC2, and
ILC3 markers yet express the pan-ILC marker, CD127, the alpha chain of the interleukin-7 (IL-7) receptor (Bernink et al., 2013) . Of note, some of the above markers are shared by ILC subsets. For instance, CD56 and NKp44 can be expressed by both ILC3s and NK cells (Cella et al., 2009; Cupedo et al., 2009) . In mice ILCs originate from bone marrow-derived common lymphoid progenitors (CLPs) (Serafini et al., 2015) . CLPs in turn yield common ILC progenitors (CILPs) that give rise to all ILCs but lack non-ILC differentiation potential (Seehus et al., 2015; Yang et al., 2015; Yu et al., 2014) . CILPs then give rise to common helper ILC progenitors (CHILPs) that can generate helper ILCs but not NK cells (Constantinides et al., 2014; Klose et al., 2014) , as well as to lineage-committed NK cell progenitors (NKPs) that can only differentiate into NK cells (Carotta et al., 2011; Fathman et al., 2011; Rosmaraki et al., 2001) . The existence of CHILPs and lineage-committed NKPs supports a divergent model for terminal murine helper ILC and NK cell development, respectively, and this model is reinforced by genetic fate-mapping studies tracing the mRNA expression of key TFs including Rorgt and Plzf (Constantinides et al., 2014; Klose et al., 2014; Satoh-Takayama et al., 2010; Vonarbourg et al., 2010) .
In humans, multipotent CD34 + CD117 À CLP-like early tonsil progenitor cells (ETPs) and CD34 + CD117 + CILPs, have been described in secondary lymphoid tissues (SLTs) such as lymph nodes and tonsils (Freud et al., 2006; Scoville et al., 2016) . In addition, systemic pan-ILC precursors (ILCPs) that are functionally similar to CILPs but that are CD34 À CD117 + were recently characterized , suggesting some similarities between murine and human ILC development. However, a human progenitor population analogous to the murine CHILP, which can differentiate into helper ILCs but not NK cells, has not been described. Furthermore, the distinct pathway by which each human ILC subset develops in vivo remains unclear (Scoville et al., 2017) .
Here we provide evidence that human NK cell, ILC2, and ILC3 development occurs sequentially within tonsils from CD34 + CD117
À ETPs through CD34 + CD117 + CILP and CD34 À CD117 + ILCP intermediates that in turn give rise to terminally differentiated ILCs. Whereas we did not identify a human CHILP analogous to that described in mice, we did identify a CD56 + subset of CD34
À

CD117
+ ILCPs that exclusively gave rise to NK cells and ILC3s but not to ILC2s. Our findings support a model in which human NK cells and ILC3s can share a common developmental pathway separate from that of ILC2s.
RESULTS
Putative NK Cell, ILC2, and ILC3 Developmental Pathways Exist in Human Tonsils
Based on previous discoveries of lymphoid progenitor and precursor populations in human SLTs (Freud et al., 2005; Lim et al., 2017; Montaldo et al., 2014; Renoux et al., 2015; Scoville et al., 2016) , we hypothesized that human ILCs share a common developmental pathway in SLTs and that at some point each ILC subset terminally differentiates along its own developmental trajectory. To test this hypothesis, we first used mass cytometry (Behbehani et al., 2015) together with visual Stochastic Network Embedding (viSNE) analyses (Amir el et al., 2013) . Excluding Lin + cells via biaxial gating, 25 ILC associated markers were configured into two dimensions, t-SNE1 and t-SNE2 (Table S1 , antibodies labeled with ''(v)''). CD34, CD117, CD94, KLRG1, and NKp44 were particularly useful in identifying distinct clusters of CD34 ILC3s in the two dimensional viSNE plots (Figure 1 ). In contrast, we did not detect distinct clusters of ILC1s (data not shown), likely due to the rarity of ILC1s in healthy donor human tonsils (Bernink et al., 2013; Simoni et al., 2017; Vé ly et al., 2016) . The above cell cluster designations were further supported by viSNE plots showing expression data of other ILC subset associated markers ( Figures 1A and S1 ), and suggested hierarchical relationships stemming from the CD34 + ETP and CILP cluster (Figure 1B, left box) . Additionally, the expression patterns of NKp44, CD161, and CD56 suggested that some developing NK cells can differentiate from an ILC3 phenotype ( Figure 1B , red dashed arrows) as has been recently proposed (Freud et al., 2016; Hughes et al., 2014 Figure 2A , red events) were identified as Lin À cells (i.e., lacking CD3, CD4, CD5, CD14, CD19, CD20, CD123, and FcεR1a) that expressed one or more of the following: CD16, CD94, NKG2A, NKG2C, NKp80, KIR2D, and/or KIR3DL1-2; ILC2s (''ILC2'' in Figure 2B , blue events) were identified as Lin À NK À cells that expressed CD294 and/or KLRG1;
and ILC3s (''ILC3'' in Figure 2C , green events) were identified as Lin
+ ILC1s were again scarcely detected ( Figure 2D , purple box and data not shown, n = 11), consistent with other reports (Bernink et al., 2013; Simoni et al., 2017; Vé ly et al., 2016) . Therefore we focused on investigating NK cell, ILC2, and ILC3 development in the tonsils. In accordance with prior findings (Freud et al., 2006) (Figure 2A , left plot, red dashed arrow). Because CILPs express both CD34 and CD117 , the putative NK cell developmental pathway ultimately stemming from CD34 + CD117 À ETPs should run as illustrated by the red arrow in the middle plot of Figure 2A . Moreover, since immature NK cells express CD117 before they acquire CD16 or KIRs (Matos et al., 1993) , we charted the NK cell developmental pathway as traversing through Lin Figure 2A , right plot). Thus, CD117 represented a useful bridging marker for the putative NK cell developmental pathway stemming from CD34 + progenitors in the tonsil. Excluding NK cells from the analyses (Figure 2A, Figure 2C , left plot) yet ILC3s are derived from CD34 + CD117 + CILPs and co-express both CD117 and NKp44 when functionally mature (Cella et al., 2009; Cupedo et al., 2009 ). Thus, we could illustrate the putative ILC3 developmental pathway as also traversing a CD117 + intermediate population losing CD34 and lacking NKp44 ( Figure 2C , middle and right plots) and then ultimately acquiring NKp44 ( Figure 2C , green arrow in right plot). Small numbers of Lin
NKp44
+ cells were also detected in the tonsils ( Figure 2C , green box in right plot) consistent with a previous report (Bernink et al., 2013) , but the ex vivo immunophenotypic and functional characteristics of this minor population have not been extensively evaluated. In considering that Lin
represent a minor subset of ILC3s we included this population in our analyses and referred to it as CD117 À ILC3s.
Finally, as shown in the left plot in Figure 2C (purple brackets) and in Figure 2D , the tonsil-resident Lin
+ population expressed CD127 consistent with Figure 3A ). Similarly, the 2D dot plots in Figure 3B show that while mature ILC markers were not detected when gating on total Lin Figure 3C , left plot). Although mature markers from all three ILC subsets were detected when gating on Lin Figure 3C , top row), only NK cell and ILC3 associated markers were detected when gating on Lin À CD34 À CD117 + CD56 + cells ( Figure 3C , bottom row). These data and those described in Figures 1 and 2 suggested that the human tonsillar ILC2 developmental pathway diverges from a shared NK cell and ILC3 Representative flow cytometry analyses of freshly enriched human tonsil ILCs after exclusion of lineage antigens (CD3, CD4, CD5, CD14, CD19, CD20, CD123, and FcεR1a), henceforth referred to as Lin À . (A) Depiction of the human NK cell developmental pathway, in which the ''NK'' axis label = CD16, CD94, NKG2A, NKG2C, NKp80, KIR2D, and KIR3DL1-2. Antibodies targeting all seven NK cell markers were evaluated together in the same channel by flow cytometry. NK cells were painted red in the plots, which were gated on Lin À lymphocytes.
(B) Depiction of the putative human ILC2 developmental pathway, in which the ''ILC2'' axis label = CD294 and KLRG1. Antibodies targeting both ILC2 markers were evaluated together in the same channel by flow cytometry. ILC2s were painted blue in the plots, which were gated on Lin
(C) Depiction of the putative human ILC3 developmental pathway, in which the ''ILC3'' axis label = NKp44. ILC3s were painted green in the plots, which were gated on Lin Table S2 and were freshly purified as shown in Figure S2 . First, we performed total RNA sequencing analysis of each of the ten populations freshly purified from each of three donors' tonsil specimens. Figure 4A shows a heatmap and unsupervised hierarchical clustering of the 30 sorted samples according to the relative expression of the 431 most differentially expressed Figure 4B ). Principle component analyses (PCA) also revealed distinct transcriptional profiles of the ten populations freshly isolated from the three human tonsils. For example, the PC 2 versus PC 3 plot shown in Figure 4C demonstrated that each of the ten populations from each donor's tonsil clustered with the respective population from each of the other two donors' tonsils (e.g., all three donors' ETPs clustered together, etc.). In addition, the PCA shown in Figure 4C revealed and for their expression of known ILC subset-associated markers. First, we stimulated enriched tonsil ILCs and progenitor cells with either ILC subset-specific cytokines for 24 hours or with phorbol 12-myristate 13-acetate (PMA), ionomycin, and IL-2 (PMA-I-2) for 6 hours and then assessed for intracellular cytokine production via flow cytometry. As predicted, the NK cells, ILC2s, and ILC3s produced IFN-g, IL-13, and IL-22, respectively, whereas ETPs, CILPs, and CD56 À/+ ILCPs did not produce detectable amounts of these cytokines ( Figure S3 ). We also observed that the proportions of cytokine + cells were significantly higher among CD117
À ILCs compared with their respective CD117 + ILCs in the ILC-specific stimulation conditions for NK cells and ILC3s and also in the PMA-I-2 condition for NK cells and ILC2s ( Figures 5A-5C ). These data indicated that the capacities for mature ILC subset associated cytokine production were first acquired downstream of the ILCP stages of development. In addition, the data also indicated that while very rare in the tonsils, CD117 À ILC3s were qualitatively and functionally similar to CD117 + ILC3s. (B) Top ten expressed genes among the 431 total genes that differentiate the ten tonsil-derived populations.
(C) PCA of the ten populations based on the average expression of the variable genes. Each population was sorted from n = 3 tonsils from one experiment. See also Figure S2 and Table S2 .
Next we characterized the ex vivo expression patterns of known ILC-associated surface markers and transcription factors using flow cytometry of freshly en- + CILPs) and progeny (CD117 + ILCs). Therefore, in conjunction with the ex vivo flow cytometry patterns described earlier ( Figure 3C ), the extensive phenotypic data shown in Figure 5 indicated that CD56 was unique among all of the markers tested in denoting a possible point of ILC2 divergence from NK cells and ILC3s at the level of CD34 À CD117 + ILCPs.
CD56 + ILCPs Can Produce NK Cells and ILC3s but Not ILC2s
Given our ex vivo phenotypic data suggesting that CD56 marks a point of divergence of ILC2s from NK cells and ILC3s ( Figure 3C ), we tested the hypothesis that freshly purified tonsillar CD56 À and CD56 + ILCPs have distinct lineage differentiation potentials.
Each CD34 À CD117 + ILCP subset was freshly sorted by CD56 expression from tonsils to R 98% purity ( Figure S2 ) and then cultured in vitro for 28 days with murine OP9-DL1 stroma plus recombinant human Flt3 ligand (FL) and IL-7. These in vitro conditions were used because they support the simultaneous development of NK cells, ILC2s, and ILC3s from CD34 + CD117 À ETPs and CD34 + CD117 + CILPs . In addition, the ILCs produced under these in vitro conditions were similar to those freshly purified from tonsils with regards to the specific associations of ILC subset associated surface markers with their respective cytokines and RORgt expression ( Figure S4 ). Of note, only minute populations of putative non-NK ILC1s (defined functionally) were detected (< 1% of total ILCs, n = 10, Figures  S4A and S4B, black boxes in left plots), similar to what we previously observed when evaluating CD34 + CD117 + CILP-derived
ILCs generated under the same conditions Error bars in (A)-(C) indicate SEM. *p < 0.05, **p < 0.01,****p < 0.0001, ns = not significant. See also Figure S3 and Tables S2 and S4. ulations (data not shown) (Freud et al., 2016) . In addition, these bulk culture findings were further substantiated by data obtained from clonal culture assays initiated with individually sorted CD56 À ILCPs or CD56 + ILCPs and supplemented with stem cell factor (SCF) and IL-2 during the first two weeks of culture to facilitate proliferation (Yang et al., 2015) . The observation that in vitro lineage differentiation plasticity was retained by the population of tonsillar CD117 + NK cells (Figures 6D and S5 ) argues against the notion of early-stage NK cell lineage commitment, which has been proposed to occur at the level of a CD34 + NKP (Renoux et al., 2015) . Indeed tonsil-derived human CD34 À CD117 + ILCPs gave rise to both NK cells and non-NK ILCs in vivo following transplantation into busulfan-pretreated nonobese diabetic (NOD)-scid IL2Rgammanull (NSG) immunodeficient mice that were then injected twice weekly for 4 weeks with recombinant human FL, SCF, IL-1b, IL-2, IL-7, IL-15, and IL-23 ( Figure S7A ), consistent with findings by the Di Santo laboratory 
CD45
+ subset produced in each experiment (n = 13) ( Figures S7B-S7E) . Collectively, these data support the notion that human NK cell lineage differentiation commitment occurs at a late stage of development in the tonsil.
CILPs and CD56
-ILCPs Can Differentiate into CD56 + ILCPs The combined ex vivo cytometric, transcriptional, phenotypic, and functional data described above supported a model whereby human NK cells, ILC2s, and ILC3s can develop in ton- Figure 7A ) and tonsil-derived CD56 À ILCPs ( Figure 7B) ILCPs. These precursor-progeny relationships are depicted in a comprehensive model of human tonsil ILC development shown in Figure 7D .
DISCUSSION
In the murine system, multiple elegant adoptive transfer and genetic fate-mapping studies have facilitated the identification of key steps and cellular intermediates in the development of each ILC subset (Constantinides et al., 2014; Klose et al., 2014; Satoh-Takayama et al., 2010; Vonarbourg et al., 2010) . These data have in turn led to the generation and wide acceptance of a comprehensive model of mouse ILC development, providing a fundamental framework for ongoing investigations into the molecular regulation of innate lymphopoiesis (Zook and Kee, 2016) . Recent studies have also identified human progenitor populations that appear to be analogous to those described in mice (Freud et al., 2006; Lim et al., 2017; Montaldo et al., 2014; Renoux et al., 2015; Scoville et al., 2016) . However, the complete picture of human ILC development has remained less well defined than its murine counterpart (Scoville et al., 2017) . In this study, we performed an extensive ex vivo phenotypic, molecular, and functional analysis of fresh, human, tonsil-derived, Lin À lymphoid cells in order to formulate a comprehensive model of human NK cell, ILC2, and ILC3 development in mucosal SLTs. Working under the premises that human ILCs ultimately derive from CD34 + progenitor cells and can develop in these tissues, we provide evidence for the coexistence and partial overlap of NK cell, ILC2, and ILC3 developmental continuums in human tonsils. Specifically, our data suggest that each of these ILC subsets can develop along a shared pathway starting from CD34 + ILCP population appears to represent a pool of restricted NK cell and ILC3 precursors, which to the best of our knowledge has not been described in mice or humans. Notably, our ex vivo immunophenotypic and single-cell clonal culture data also failed to provide any concrete evidence for the existence of a human tonsil-resident CHILP population analogous to the CHILP described in mice (Constantinides et al., 2014; Klose et al., 2014) . Therefore, our studies highlight potential major distinctions between human and mouse ILC development, with human ILC2s diverging away from a shared NK and ILC3 developmental pathway. Nonetheless we note that while we used tonsils as the source of human ILC developmental intermediates in this study, many studies of mouse ILC development were performed using fetal liver-and/or bonemarrow-derived progenitor cells (Constantinides et al., 2014; Klose et al., 2014; Serafini et al., 2014) . Therefore, some of these differences between human and mouse ILC development might be related to tissue-specific effects. Further investigation will be necessary to determine to what extent proposed models of human and mouse ILC development are applicable across a broad range of tissues including non-lymphoid tissues where ILCs might be resident and develop locally (Gasteiger et al., 2015; Lim et al., 2017; Moro et al., 2016) . In light of the association of CD56 with the NK cell and ILC3 developmental pathways, we note that CD56 expression was bimodally expressed on the tonsil ILC3 populations. Therefore, while it is anticipated that CD34 progenitor populations such as ILC3 lineage-specified progenitors (Montaldo et al., 2014) and NKPs (Renoux et al., 2015) . Indeed it was previously shown that cells designated as ILC3 lineage-specified progenitor cells, which express CD34 and CD117 and hence phenotypically overlap with CD34 + CD117 + CILPs, can also give rise to non-ILC3 cells in vitro and in vivo (Freud et al., 2006; Scoville et al., 2016) . Likewise, we demonstrated in this study that fresh tonsil-derived putative human NKPs, which express CD34 and CD10 and hence phenotypically overlap with CD34 + CD117 À ETPs, gave rise to heterogeneous mixtures of T cells and ILCs following in vitro culture under the conditions used in this study. Therefore, the principle of early lineage commitment may not be entirely accurate, at least with regards to human ILC development in the tonsil. Continued investigation of this process is warranted.
In light of the above, our findings do not exclude the possibility that other ILC differentiation pathways exist in other tissues.
Indeed CD34
+ progenitor cells similar to those present in human SLTs also exist in the liver, intestine, and uterus (Yu et al., 2013) . Likewise, human fetal liver, umbilical cord blood, adult lungs, and adult peripheral blood harbor CD34 À CD117 + ILCPs , which are phenotypically and functionally similar to CD56 À ILCPs in tonsils. Additionally, mesenchymal cells were recently shown to support late-stage ILC differentiation in peripheral tissues (Koga et al., 2018 
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METHODS DETAILS
Cell isolation, Selection, and Sorting Human ILCs were enriched from fresh tonsil specimens as previously described (Scoville et al., 2015) . When appropriate, the following selections were performed from enriched ILC populations: 1) CD34 + selection using the Indirect CD34 MicroBead Kit (Miltenyi); 2) Biotin + selection of CD34 -cells labeled with biotinylated NK-specific surface antibodies (CD16, CD94, NKG2A, NKG2C, NKp80, KIR2D, and KIR3DL1-2) using the Anti-Biotin MicroBead Kit (Miltenyi); and 3) PE + selection of CD34 -biotin -cells labeled with PE CD117 using the Anti-PE MicroBead Kit (Miltenyi). All selections were carried out according to the manufacturer's instructions with LS columns (Miltenyi). Each population was sorted to R 98% purity with a FACSAriaII sorter (BD Biosciences) ( Figure S2 ).
Mass Cytometry
Five million enriched human ILCs were stained for mass cytometry analyses as previously described (Bendall et al., 2011; Horowitz et al., 2013) . Antibodies were purchased or labeled using Maxpar-X8 labeling reagent kits based on the manufacturer's instructions (Fluidigm). Cells were fixed with Smart tube buffer for 10 min at room temperature (RT), washed with cell staining media (CSM) and incubated with surface antibodies for 50 min at RT. Cells were then washed three times with CSM, fixed with 1.5% paraformaldehyde, and permeabilized with ice cold methanol at À20 C for 15 min. Following incubation, cells were washed thrice with CSM and stained with intracellular antibodies for 50 min at room temperature. Cells were then washed twice with CSM and incubated with iridium intercalator pentamethylcyclopentadienyl-Ir(III)-dipyridophenazine (Fluidigm) Intercalator solution with 1.5% paraformaldehyde (1:4000 dilution) at 4 C until further analysis. Excess intercalator was removed by washing cells once with CSM and twice with deionized water. Cells were re-suspended at a concentration of 1 million/ml of pure water mixed with 4 Elemental Equilibration beads (Fluidigm). Cells were acquired on a third-generation Helios mass cytometer at an event rate of 200-400 events per second. Noise reduction was utilized, sigma = 3, and the event duration and lower convolution threshold were 8-150 and 600, respectively. Data were normalized using the method of Finck et al. (Finck et al., 2013) . A compensation matrix was used to account for expected small (1%-2%) spillovers from isotopic contamination in the metal isotopes. Data were evaluated using viSNE analysis (Amir el et al., 2013) . All mass cytometry antibodies used are listed in Supplemental Experimental Procedures (Table S1 ).
Flow Cytometric Analysis of Surface and Intracellular Markers and Cytokine Production
Ex vivo and in vitro derived ILC populations were first stained with Flexible Viability Dye eFluor 506 (eBiosciences) for 10 min, followed by a 15 min surface stain with the appropriate antibodies on ice. For intracellular cytokine analysis, cells were either stimulated for 1) 24 hr with combinations of the following ILC-specific cytokines: IL-2 (1 nM) (Peprotech), IL-12 (10ng/ml), IL-15 (10ng/ml), IL-18 (10ng/ml), IL-25 (10ng/ml), IL-33 (10ng/ml), IL-1b (10ng/ml), and/or IL-23 (10ng/ml) (Miltenyi) (Bernink et al., 2015; Freud et al., 2016; Mjö sberg et al., 2011) ; or 2) 6 hr with IL-2, PMA (81 nM), and ionomycin (1.34 mM) (eBioscience). Brefeldin A (BD Biosciences) was added 4 hr prior to collection. Intracellular staining was performed using the Cytofix and Cytoperm Fixation and Permeabilization Solution Kit (BD Biosciences) for cytokine analysis or the Foxp3 Transcription Factor Staining Buffer Set (eBiosciences) for transcription factor analysis. Cells were acquired on an LSRII cytometer (BD Biosciences) and analyzed using FlowJ10 (TreeStar) as previously described . To determine nonspecific staining, the appropriate use of unstimulated controls and isotype controls was performed. All antibodies utilized for flow cytometry immunophenotyping and post culture analyses are listed in Supplemental Experimental Procedures (Table S3 ).
In Vivo Transplantation of ILC Precursors in NSG Mice
Experiments involving NSG mice (purchased from The Jackson Laboratory) were performed in accordance with a protocol approved by the OSU Institutional Animal Care and Use Committee. One day prior to injection of human ILCPs, 25 mg/kg busulfan was injected into 6-10 week old female NSG mice to promote engraftment. The following day, 40,000-50,000 tonsil-derived human CD34 -CD117 + ILCPs were sorted to R 98% purity and injected intravenously into NSG mice. At day zero and twice weekly thereafter for four weeks, the NSG mice were given intraperitoneal injections of the following recombinant human cytokines: FL, SCF, IL-1b, IL-2, IL-7, IL-15, and IL-23 (0.5 mg/mouse). After four weeks, the mice were sacrificed, and their blood, spleens, bone marrow, lungs, and small intestinal lamina propria were harvested and analyzed using flow cytometry. Murine leukocytes were excluded using an anti-mouse CD45.1 antibody and human leukocytes were positively identified using an anti-human CD45 antibody.
RNA Isolation and qPCR
Each population was sorted and mRNA isolated using the Total RNA Purification Plus Kit (Norgen Biotek). Reverse transcription was performed utilizing the Superscript VILO master mix (Life Technologies). Gene expression was normalized to 18S mRNA, and relative quantification was performed using the DDCt method. The y-axes portray fold differences in mRNA expression quantified based on the population in which expression was lowest (arbitrarily normalized to 1). All primers used are listed in Table S4 of Supplemental Experimental Procedures.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are represented as mean ± SEM unless specified. Sample sizes for each experiment and the replicate number of experiments are included in the figure legends. Linear mixed effects models were used for analysis to take into account the correlation of multiple observations from the same donor. Holm's procedure was used to control for multiple comparisons. Adjusted p values < 0.05 are considered as significant. All analyses were performed using SAS9.4 (SAS Institute, Inc., NC).
DATA AND SOFTWARE AVAILABILITY
The RNA-seq raw data files (accession numbers SAMN09767432, SAMN09767433, SAMN09767434, SAMN09767435, SAMN09767436, SAMN09767437, SAMN09767438, SAMN09767439, SAMN09767440, SAMN09767441, SAMN09767442, SAMN09767443, SAMN09767444, SAMN09767445, SAMN09767446, SAMN09767447, SAMN09767448, SAMN09767449, SAMN09767450, SAMN09767451, SAMN09767452, SAMN09767453, SAMN09767454, SAMN09767455, SAMN09767456, SAMN09767457, SAMN09767458, SAMN09767459, SAMN09767460, SAMN09767461) are available at the NCBI Gene Expression Omnibus (BioSample) archive.
